Eliana Merle
Stock Analyst at Barclays
(3.93)
# 611
Out of 5,122 analysts
106
Total ratings
51.28%
Success rate
11.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $414 → $606 | $465.61 | +30.15% | 1 | Jan 28, 2026 | |
| QURE uniQure | Initiates: Equal-Weight | $31 | $27.80 | +11.51% | 5 | Jan 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $59 | $31.25 | +88.80% | 2 | Jan 28, 2026 | |
| TPG TPG Inc. | Initiates: Overweight | $78 | $53.34 | +46.23% | 1 | Jan 28, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Equal-Weight | $8 | $6.56 | +21.95% | 2 | Jan 28, 2026 | |
| PTCT PTC Therapeutics | Upgrades: Overweight | $68 → $119 | $74.83 | +59.03% | 1 | Jan 28, 2026 | |
| MBX MBX Biosciences | Initiates: Overweight | $66 | $39.22 | +68.28% | 1 | Jan 28, 2026 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Overweight | $964 | $482.45 | +99.81% | 6 | Jan 28, 2026 | |
| IVA Inventiva | Initiates: Overweight | $18 | $6.19 | +190.79% | 2 | Jan 28, 2026 | |
| INSM Insmed | Initiates: Overweight | $231 | $157.16 | +46.98% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $2.67 | +237.08% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $224.75 | +52.17% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.49 | +247.73% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $78.18 | +2.33% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $24 | $23.32 | +2.92% | 9 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $351.80 | +49.80% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $40 → $34 | $42.20 | -19.43% | 9 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $5.47 | +338.76% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $57.75 | -84.42% | 4 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $51.21 | -60.95% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $113 → $114 | $57.61 | +97.88% | 3 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $20.28 | -40.83% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.03 | +294.09% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $13.65 | +53.85% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $77.22 | -9.35% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $2.82 | -21.99% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $95.97 | -26.02% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $108.25 | +21.02% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $24.03 | -79.19% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $38.52 | -53.27% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $20.94 | +5.06% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $10.86 | +332.78% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.28 | +12.04% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $34.60 | +287.28% | 3 | Aug 19, 2020 |
Vertex Pharmaceuticals
Jan 28, 2026
Upgrades: Overweight
Price Target: $414 → $606
Current: $465.61
Upside: +30.15%
uniQure
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $31
Current: $27.80
Upside: +11.51%
Tyra Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $31.25
Upside: +88.80%
TPG Inc.
Jan 28, 2026
Initiates: Overweight
Price Target: $78
Current: $53.34
Upside: +46.23%
Sagimet Biosciences
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $6.56
Upside: +21.95%
PTC Therapeutics
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $74.83
Upside: +59.03%
MBX Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $39.22
Upside: +68.28%
Madrigal Pharmaceuticals
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $482.45
Upside: +99.81%
Inventiva
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $6.19
Upside: +190.79%
Insmed
Jan 28, 2026
Initiates: Overweight
Price Target: $231
Current: $157.16
Upside: +46.98%
Jan 28, 2026
Initiates: Overweight
Price Target: $9
Current: $2.67
Upside: +237.08%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $224.75
Upside: +52.17%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $9.49
Upside: +247.73%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $78.18
Upside: +2.33%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $24
Current: $23.32
Upside: +2.92%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $351.80
Upside: +49.80%
Jan 7, 2026
Assumes: Neutral
Price Target: $40 → $34
Current: $42.20
Upside: -19.43%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $5.47
Upside: +338.76%
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $57.75
Upside: -84.42%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $51.21
Upside: -60.95%
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $57.61
Upside: +97.88%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $20.28
Upside: -40.83%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.03
Upside: +294.09%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $13.65
Upside: +53.85%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $77.22
Upside: -9.35%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $2.82
Upside: -21.99%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $95.97
Upside: -26.02%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $108.25
Upside: +21.02%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $24.03
Upside: -79.19%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $38.52
Upside: -53.27%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $20.94
Upside: +5.06%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $10.86
Upside: +332.78%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.28
Upside: +12.04%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $34.60
Upside: +287.28%